tradingkey.logo
搜尋

Illumina Inc

ILMN
添加自選
145.735USD
+0.035+0.02%
交易中 美東報價延遲15分鐘
22.15B總市值
26.33本益比TTM

Illumina Inc

145.735
+0.035+0.02%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.02%

5天

+4.79%

1月

+20.51%

6月

+19.47%

今年開始到現在

+11.11%

1年

+78.66%

TradingKey Illumina Inc股票評分

單位: USD 更新時間: 2026-05-12

操作建議

Illumina Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名10/206位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為141.20。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Illumina Inc評分

相關信息

行業排名
10 / 206
全市場排名
78 / 4490
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Illumina Inc亮點

亮點風險
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值26.32,處於3年歷史高位
機構減倉
最新機構持股162.52M股,環比減少8.64%
巴羅·漢利持倉
明星投資者巴羅·漢利持倉,最新持倉1.41K股

分析師目標

基於 21 分析師
買入
評級
141.197
目標均價
-0.48%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Illumina Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Illumina Inc簡介

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
公司代碼ILMN
公司Illumina Inc
CEOThaysen (Jacob)
網址https://www.illumina.com
KeyAI